COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach

被引:32
作者
Borriello, Giovanna [1 ]
Ianniello, Antonio [2 ,3 ]
机构
[1] Sapienza Univ Rome, MS Ctr, S Andrea Hosp, Rome, Italy
[2] Univ Coll London UCL, NMR Res Unit, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat,UCL Inst Neurol, London, England
[3] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy
关键词
Multiple sclerosis; Relapsing remitting multiple sclerosis; Natalizumab; Coronavirus; Covid; 19; Extended Interval Dosing;
D O I
10.1016/j.msard.2020.102165
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The novel Coronavirus SARS-CoV-2, which was identi fied after a recent outbreak in Wuhan, China, in December 2019, has generated a global pandemic impacting over 200 countries around the world. Recent reports suggest that ACE2, which is the target protein to invade the host, has a ubiquitous presence in human organs, including lung parenchyma, gastrointestinal tract, nasal mucosa, renal and urinary tract, airway epi- thelia, lymphoid tissues, reproductive organs, vascular endothelium and neurons. In this scenario, neurologists are particularly involved into considering even more speci fic therapeutic strategies according to the available data during the pandemic. In particular, MS patients are usually receiving disease -modifying therapies (DMTs) with immunosuppressant or immunomodulatory e ffects, which increase the risk of infections and morbidity, compared with the general population. Development of PML or other serious opportunistic infections during treatment with natalizumab forces to consider whether de -risking strategies are needed in this particular context and how to manage a high -e fficacy treatment. Methods: In this paper we report on a patient treated with natalizumab for relapsing MS who developed COVID- 19 and recovered in a few days without complications. Results: After recovery natalizumab has been administered in the window of the extended interval dosing (EID), without reporting any worsening or new symptoms. Discussion: This case supports the opportunity to avoid discontinuing or delaying the retreatment over 8 weeks in patients recovered from a recent COVID-19.
引用
收藏
页数:2
相关论文
共 5 条
  • [1] Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
    Clerico, Marinella
    De Mercanti, Stefania Federica
    Signori, Alessio
    Iudicello, Marco
    Cordioli, Cinzia
    Signoriello, Elisabetta
    Lus, Giacomo
    Bonavita, Simona
    Lavorgna, Luigi
    Maniscalco, Giorgia Teresa
    Curti, Erica
    Lorefice, Lorena
    Cocco, Eleonora
    Nociti, Viviana
    Mirabella, Massimiliano
    Baroncini, Damiano
    Mataluni, Giorgia
    Landi, Doriana
    Petruzzo, Martina
    Lanzillo, Roberta
    Gandoglia, Ilaria
    Laroni, Alice
    Frangiamore, Rita
    Sartori, Arianna
    Cavalla, Paola
    Costantini, Gianfranco
    Sormani, Maria Pia
    Capra, Ruggero
    [J]. NEUROTHERAPEUTICS, 2020, 17 (01) : 200 - 207
  • [2] MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study
    Fox, Robert J.
    Cree, Bruce A. C.
    De Seze, Jerome
    Gold, Ralf
    Hartung, Hans-Peter
    Jeffery, Douglas
    Kappos, Ludwig
    Kaufman, Michael
    Montalban, Xavier
    Weinstock-Guttman, Bianca
    Anderson, Britt
    Natarajan, Amy
    Ticho, Barry
    Duda, Petra
    [J]. NEUROLOGY, 2014, 82 (17) : 1491 - 1498
  • [3] Liu M., 2020, China Lancet, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30183-5]
  • [4] COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features
    Poyiadji, Neo
    Shahin, Gassan
    Noujaim, Daniel
    Stone, Michael
    Patel, Suresh
    Griffith, Brent
    [J]. RADIOLOGY, 2020, 296 (02) : E119 - E120
  • [5] Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI [10.1172/JCI89857, 10.1056/NEJMoa2001017]